Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo J L, Zelniker, Thomas A, Dwyer, Jamie P, Bhatt, Deepak L, Leiter,Journal:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(19)30180-9
Date:
June, 2019
File:
PDF, 1.32 MB
2019
File converter
More search results
More benefits 
